We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos and CRT Announce Anti-Cancer Drug Discovery Collaboration
News

Galapagos and CRT Announce Anti-Cancer Drug Discovery Collaboration

Galapagos and CRT Announce Anti-Cancer Drug Discovery Collaboration
News

Galapagos and CRT Announce Anti-Cancer Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos and CRT Announce Anti-Cancer Drug Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV and Cancer Research Technology (CRT), a wholly owned company of Cancer Research UK, have announced that they have entered into collaboration in anti-cancer drug discovery research.

Under the terms of the agreement Galapagos' service division BioFocus will perform medicinal chemistry services on a series of CRT anti-cancer drug programs.

In return, CRT will fund the work of four BioFocus scientists throughout 2006.

"This agreement testifies to the high quality of BioFocus' medicinal chemistry expertise and the overall competitiveness of our integrated services portfolio," said Onno van de Stolpe, CEO of Galapagos. 

"We also are pleased to assist Cancer Research Technology in the fight against cancer."
 
"CRT has succeeded in forming a number of collaborative anti-cancer programs with academic and commercial partners alike," added Tony Raynham, CRT's Head of Medicinal Chemistry. 

"Our relationship with BioFocus, in conjunction with existing in-house R&D resource, will ensure that these programs are advanced rapidly through early-stage development, thereby creating robust licensing opportunities and cancer patient benefit."

Advertisement